When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
Background The impact of different types of extracranial bleeding events on health‐related quality of life and health‐state utility among patients with atrial fibrillation is not well understood . Methods and Results The ENGAGE AF‐TIMI 48 ( Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation – Thrombolysis in Myocardial Infa rct ion 48 ) Trial compared edoxaban with warfarin with respect to the prevention of stroke or systemic embolism in atrial fibrillation . Data from the EuroQol‐5D ( EQ‐5D‐3L ) question naire , prospect ively collected at 3‐month intervals for up to 48 months , were used to estimate the impact of different categories of bleeding events on health‐state utility over 12 months following the event . Longitudinal mixed‐effect models revealed that major gastrointestinal bleeds and major nongastrointestinal bleeds were associated with significant immediate decreases in utility scores ( −0.029 [ −0.044 to −0.014 ; P<0.001 ] and −0.029 [ −0.046 to −0.012 ; P=0.001 ] , respectively ) . These effects decreased in magnitude over time , and were no longer significant for major nongastrointestinal bleeds at 9 months , but remained borderline significant for major gastrointestinal bleeds at 12 months . Clinical ly relevant nonmajor and minor bleeds were associated with smaller but measurable immediate impacts on utility ( −0.010 [ −0.016 to −0.005 ] and −0.016 [ −0.024 to −0.008 ] ; P<0.001 for both ) , which remained relatively constant and statistically significant over the 12 months following the bleeding event . Conclusions All categories of bleeding events were associated with negative impacts on health‐state utility  in patients with atrial fibrillation . Major bleeds were associated with relatively large immediate decreases in utility scores that gradually diminished over 12 months ; clinical ly relevant nonmajor and minor bleeds were associated with smaller immediate decreases in utility that persisted over 12 months . Clinical Trial Registration URL : https://www . clinical trials.gov/. Unique identifier : NCT00781391
When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .